PUBLICATION
Preclinical evaluation of platinum-loaded hydroxyapatite nanoparticles in an embryonic zebrafish xenograft model
- Authors
- Nadar, R.A., Asokan, N., Degli Esposti, L., Curci, A., Barbanente, A., Schlatt, L., Karst, U., Iafisco, M., Margiotta, N., Brand, M., van den Beucken, J.J.J.P., Bornhäuser, M., Leeuwenburgh, S.C.G.
- ID
- ZDB-PUB-200620-16
- Date
- 2020
- Source
- Nanoscale 12(25): 13582-13594 (Journal)
- Registered Authors
- Brand, Michael
- Keywords
- none
- MeSH Terms
-
- Animals
- Breast Neoplasms*/drug therapy
- Cell Line, Tumor
- Durapatite
- Heterografts
- Humans
- Nanoparticles*
- Platinum
- Xenograft Model Antitumor Assays
- Zebrafish
- PubMed
- 32555916 Full text @ Nanoscale
Citation
Nadar, R.A., Asokan, N., Degli Esposti, L., Curci, A., Barbanente, A., Schlatt, L., Karst, U., Iafisco, M., Margiotta, N., Brand, M., van den Beucken, J.J.J.P., Bornhäuser, M., Leeuwenburgh, S.C.G. (2020) Preclinical evaluation of platinum-loaded hydroxyapatite nanoparticles in an embryonic zebrafish xenograft model. Nanoscale. 12(25):13582-13594.
Abstract
Hydroxyapatite (HA) nanoparticles are commonly used as building blocks in the design of bone-substituting biomaterials. Recently, these nanoparticles have been considered for the treatment of metastasis disease, since their pH-dependent dissolution behavior allows for precise tuning of release kinetics of loaded cargo. Herein we show that the capacity of drug-loaded nanoparticles stabilized with citrate ions reduce cancer cell survival in an embryonic zebrafish xenograft model. In particular, in vitro studies demonstrate that PtPP-loaded HA nanoparticles exhibit anti-proliferative activity against breast cancer cells at reduced pH. In vivo studies using an embryonic zebrafish xenograft model reveal that PtPP co-delivered with human breast cancer cells strongly reduce cancer cell survival. Similarly, co-injection of breast cancer cells with citrate-functionalized and PtPP-loaded HA nanoparticles into zebrafish significantly reduces survival of cancer cells due to release of chemotherapeutically active kiteplatin species. These results demonstrate the preclinical efficacy of drug-loaded nanoparticles against human breast cancer cells in a xenogenic embryonic in vivo model.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping